BioSpace News Archive

MAIA Biotechnology, Inc. (NYSE American: MAIA ) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences as follows.

SCOHIA PHARMA, Inc and Kuria Therapeutics, Inc. today announced that the U.S. Patent Office has issued a composition-of-matter patent covering SCO-116, a novel Nrf2 activator being developed by Kuria for prevention and treatment of eye and skin diseases.

Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round.

Cardio Diagnostics Holdings Inc and Healing Sanctuary Clinic announced the availability of Cardio Diagnostics’ Epi+Gen CHD test in Idaho.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).

HeartBeam, Inc. announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the European Patent Office.

INVO Bioscience, Inc. announced it has entered an exclusive distribution agreement with Ming Mei Technology Co. Ltd for Taiwan.

Jnana Therapeutics announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 3:30 p.m. PT.

Lantern Pharma Inc. (NASDAQ: LTRN) today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL).

Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, announced the completion of an $85 million financing.